Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Author:
Funder
Ministerio de Ciencia y Tecnología
Natural Science Foundation of Anhui Province
National Key Research and Development Program of China
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference95 articles.
1. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial;Ahn;J. Thorac. Oncol.,2016
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
3. General methods for monitoring convergence of iterative simulations;Brooks;J. Comput. Graph. Stat.,1998
4. Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504;Cadranel;Eur. Respir. J.,2015
5. Graphical tools for network meta-analysis in STATA;Chaimani;PLoS One,2013
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-09-11
2. A systematic survey of 200 systematic reviews with network meta-analysis (published 2020–2021) reveals that few reviews report structured evidence summaries;Journal of Clinical Epidemiology;2024-09
3. Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients;Acta Dermato-Venereologica;2024-08-28
4. Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example;Frontiers in Pharmacology;2024-08-13
5. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China;BMJ Open;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3